Trial Profile
An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure
- Focus Diagnostic use
- Sponsors GE Healthcare
- 25 Jun 2014 New trial record